Beam Therapeutics

Forecast & Rating15 analysts currently cover Beam Therapeutics, with about 86.7% giving a positive rating — meaning they expect the stock to rise. The average price target is $52.31, about 108.4% upside from the current price of $25.10. Price targets range from $26.00 to $80.00 — a wide spread, showing clear disagreement over just how much Beam Therapeutics can rise. Historically, about 17.8% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Beam Therapeutics closely still see room for the stock to rise. Data as of Jul 17, 2026; for reference only and not investment advice.